| Name | Title | Contact Details |
|---|
At SI Group, we create smart chemistry that solves global challenges and makes great things possible. We create smart chemistry that solves global challenges and makes great things possible. SI Group is a performance additives and intermediates business. We offer a broad array of products that feed into diverse applications including pharmaceuticals; plastics; oil and gas; and tires, among many others. We create solutions that provide formulators and manufacturers with the ability to increase efficacy, efficiency, productivity, and purity in countless industrial and consumer goods. Our company unites us. So do our values and the approach that we bring into the workplace each day.
Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications, and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions.
Global CMO for medical device & component manufacturing
US Medical Innovations, LLC is a privately-held FDA registered Plasma Medicine company developing products for Laparoscopic, Robotic and Cancer surgeries.
Creating precisely tuned medicines so patients can breathe freely, we are pioneering a new therapeutic approach to treat debilitating ear, nose and throat diseases that impact the lives of millions of people. Lyra Therapeutics is a clinical-stage company pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people. Our goal is to transform the ENT treatment paradigm by providing effective front-line solutions for physicians and new treatment options for their patients. Lyra`s transmucosal therapeutic system, now being evaluated in a clinical study, directly targets tissues that are difficult or impossible to access with existing therapies. Building on expertise in materials science, drug development and formulation, the Lyra team has developed a proprietary platform that enables sustained, local delivery of medications over an extended period of time. Based on clinical results, this new therapeutic approach has the potential to provide significantly improved patient outcomes beyond the limited treatment and surgical options currently available for ENT diseases. Headquartered in the Boston area, Lyra Therapeutics was founded by George Whitesides and Robert Langer, academic luminaries in the fields of chemistry, materials science and biotechnology, and is backed by leading life science investors.